MX2020005366A - Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. - Google Patents

Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2020005366A
MX2020005366A MX2020005366A MX2020005366A MX2020005366A MX 2020005366 A MX2020005366 A MX 2020005366A MX 2020005366 A MX2020005366 A MX 2020005366A MX 2020005366 A MX2020005366 A MX 2020005366A MX 2020005366 A MX2020005366 A MX 2020005366A
Authority
MX
Mexico
Prior art keywords
substituent
compounds
disease
treatment
parkinson
Prior art date
Application number
MX2020005366A
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Martin Juhl
Lisbet Kværnø
Jørgensen Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2020005366A publication Critical patent/MX2020005366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula (I), que son profármacos de catecolamina para uso en el tratamiento de enfermedades y trastornos neurodegenerativos. La presente invención proporciona también composiciones farmacéuticas que comprenden compuestos de la invención y métodos de tratar enfermedades y trastornos neurodegenerativos o neuropsiquiátricos utilizando los compuestos de la invención, en particular la enfermedad de Parkinson. Por consiguiente, la presente invención se relaciona con compuestos de la fórmula (Id) en donde R1 es H y R2 se selecciona de uno de los sustituyentes (i) y (ii) más adelante; o R1 se selecciona de uno de los sustituyentes (i) y (ii) más adelante y R2 es H; o R1 y R2 se representan ambos por el sustituyente (i) más adelante; o R1 y R2 se representan ambos por el sustituyente (ii) más adelante; o R1 es sustituyente (i) y R2 es sustituyente (ii); o R1 es sustituyente (ii) y R2 es sustituyente (i); en donde * indica el punto de unión; y en donde el átomo de carbono en el punto de unión en el sustituyente (i) está en la configuración S; o una sal farmacéuticamente aceptable del mismo.
MX2020005366A 2017-11-24 2018-11-23 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. MX2020005366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24
PCT/EP2018/082361 WO2019101917A1 (en) 2017-11-24 2018-11-23 New catecholamine prodrugs for use in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2020005366A true MX2020005366A (es) 2020-08-13

Family

ID=64661284

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005366A MX2020005366A (es) 2017-11-24 2018-11-23 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2022016276A MX2022016276A (es) 2017-11-24 2020-07-13 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016276A MX2022016276A (es) 2017-11-24 2020-07-13 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.

Country Status (25)

Country Link
US (4) US10729710B2 (es)
EP (1) EP3713933A1 (es)
JP (4) JP7320507B2 (es)
KR (1) KR20200092955A (es)
CN (3) CN117599073A (es)
AR (1) AR113908A1 (es)
AU (2) AU2018371193B2 (es)
BR (1) BR112019014981A2 (es)
CA (1) CA3082757A1 (es)
CL (1) CL2020001343A1 (es)
CO (1) CO2020006224A2 (es)
CR (1) CR20200225A (es)
EA (1) EA202090987A8 (es)
EC (1) ECSP20030074A (es)
GE (1) GEP20227446B (es)
IL (1) IL274648A (es)
JO (1) JOP20200114A1 (es)
MA (1) MA50800A (es)
MX (2) MX2020005366A (es)
PE (1) PE20211290A1 (es)
PH (1) PH12020550631A1 (es)
SG (1) SG11202004461YA (es)
TW (1) TWI816716B (es)
UA (1) UA127575C2 (es)
WO (1) WO2019101917A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113727974A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113677675A (zh) 2019-05-21 2021-11-19 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208865A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
LU88619I2 (fr) 1981-10-16 1995-07-10 Sandoz Ag QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
PH22782A (en) 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
IL151614A0 (en) 2000-04-07 2003-04-10 Tap Holdings Inc Apomorphine derivatives and methods for their use
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
MXPA03001272A (es) 2000-08-11 2004-04-02 Purdue Research Foundation Procedimiento para la preparacion de dinapsolina.
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
EP1414457B1 (en) 2001-08-10 2007-06-20 Purdue Research Foundation Chiral dinapsoline
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
BR0308567A (pt) 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
JP2007516292A (ja) 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
US20070254906A1 (en) 2004-07-21 2007-11-01 Darpharma, Inc. Method of Administration of Dopamine Receptor Agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP4295909A2 (en) 2016-04-20 2023-12-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113677675A (zh) 2019-05-21 2021-11-19 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727974A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2023013012A (ja) * 2021-07-15 2023-01-26 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
AU2023201741A1 (en) 2023-04-20
JP7320507B2 (ja) 2023-08-03
US11707476B2 (en) 2023-07-25
WO2019101917A1 (en) 2019-05-31
IL274648A (en) 2020-06-30
MA50800A (fr) 2020-09-30
JP7443606B2 (ja) 2024-03-05
CA3082757A1 (en) 2019-05-31
EA202090987A8 (ru) 2020-09-29
TW201924693A (zh) 2019-07-01
JP7320684B2 (ja) 2023-08-03
GEP20227446B (en) 2022-12-12
AR113908A1 (es) 2020-06-24
SG11202004461YA (en) 2020-06-29
EA202090987A1 (ru) 2020-08-07
JP2023055830A (ja) 2023-04-18
KR20200092955A (ko) 2020-08-04
PE20211290A1 (es) 2021-07-20
AU2018371193A1 (en) 2020-06-11
US20190160083A1 (en) 2019-05-30
TWI816716B (zh) 2023-10-01
CN111386267A (zh) 2020-07-07
CN117653649A (zh) 2024-03-08
CN111386267B (zh) 2023-12-12
MX2022016276A (es) 2023-02-09
US20200338102A1 (en) 2020-10-29
EP3713933A1 (en) 2020-09-30
US20240156851A1 (en) 2024-05-16
JOP20200114A1 (ar) 2020-05-17
BR112019014981A2 (pt) 2020-04-07
JP2023145579A (ja) 2023-10-11
AU2018371193B2 (en) 2022-12-22
RU2020116419A (ru) 2021-12-27
ECSP20030074A (es) 2020-07-31
CO2020006224A2 (es) 2020-05-29
US11110110B2 (en) 2021-09-07
CL2020001343A1 (es) 2020-09-25
JP2023145580A (ja) 2023-10-11
US20220257623A1 (en) 2022-08-18
CR20200225A (es) 2020-07-25
JP2021504345A (ja) 2021-02-15
PH12020550631A1 (en) 2021-02-22
CN117599073A (zh) 2024-02-27
UA127575C2 (uk) 2023-10-18
US10729710B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2022005399A (es) Compuestos.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
TN2018000299A1 (en) Heterocyclic compound.
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2021004085A (es) El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep).
MX2021007551A (es) Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas.
MX2021001273A (es) Métodos para tratar trastornos neurodegenerativos.
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6